Generic Name and Formulations:
Procarbazine (as HCl) 50mg; caps.
Sigma-Tau Pharmaceuticals, Inc.
Indications for MATULANE:
Stage III and IV Hodgkin's disease as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen.
Initially 2–4mg/kg per day for the first week, then 4–6mg/kg per day until max response is obtained or until WBCs <4,000cells/mm3 or platelets <100,000cells/mm3. Maintain at 1–2mg/kg per day once max response attained. In MOPP regimen: 100mg/m2 daily for 14 days.
Individualize. Initially 50mg/m2 per day for the first week, then 100mg/m2 per day until max response is obtained or leukopenia or thrombocytopenia occurs. Maintain at 50mg/m2 per day once max response attained.
Inadequate marrow reserve.
Discontinue if CNS effects (eg, paresthesias, neuropathies, confusion), leukopenia, thrombocytopenia, hypersensitivity reactions, stomatitis, diarrhea, hemorrhage or bleeding tendencies occur. Hepatic or renal impairment. Obtain baseline CBCs with differential, hemoglobin, hematocrit, reticulocytes, platelets prior to therapy, then monitor at least every 3–4 days. Do renal and hepatic function tests before starting therapy, then repeated weekly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Avoid sympathomimetics, tricyclic antidepressants (eg, amitriptyline, imipramine), foods with high tyramine content (eg, wine, yogurt, ripe cheese, bananas). CNS depression with barbiturates, antihistamines, narcotics, hypotensive agents, phenothiazines. Disulfiram-like reactions with alcohol. Separate radiation or other myelosuppressives by at least 1 month (allow for bone marrow recovery).
Leukopenia, anemia, thrombopenia, GI upset, bleeding tendencies, CNS effects, dysphagia, anorexia, abdominal pain, hypotension, tachycardia, syncope, cough, alopecia, dermatitis, pain, others.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|